Klebsiella pneumoniae Drug Development Pipeline Study, H2 2018

August 2018
90 pages
ID: 5483459
Format: PDF
VPAResearch

Summary

Table of Contents

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies

Klebsiella pneumoniae Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Klebsiella pneumoniae pipeline products.

DISEASE OVERVIEW
Klebsiella pneumoniae belongs to the class of Gram-negative bacteria, primarily spread from person-to-person contact or environment but not through air. In normal conditions, Klebsiella Pneumoniae lives in intestines and is not dangerous in healthy individuals. However, based on the route of entry of the bacteria, different infections such as pneumonia, blood/ wound-infections, meningitis etc. occur.

As some of the bacteria are highly resistant to antibiotics, infections caused by the bacteria are difficult for treatment. Accordingly, 25+ companies are investing their resources in development of Klebsiella pneumonia infection treatment pipeline compounds.

Companies currently investing in Klebsiella Pneumoniae pipeline development include- ABAC Therapeutics SA, Abgentis Limited, AmpliPhi Biosciences Corporation, Appili Therapeutics Inc, Arsanis Inc, C3J Therapeutics Inc, ContraFect Corporation, Debiopharm International SA, EnBiotix Inc, Evaxion Biotech ApS, Fedora Pharmaceuticals Inc, Forge Therapeutics Inc, Innovation Pharmaceuticals Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Nosopharm SAS, Oryn Therapeutics LLC, Phico Therapeutics Ltd, Shionogi & Co Ltd, Spero Therapeutics Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc, Vaxdyn SL and Vaxxilon AG.

REPORT DESCRIPTION
The Klebsiella pneumoniae pipeline guide presents complete overview of drugs currently being developed for Klebsiella pneumoniae. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Klebsiella pneumoniae pipeline candidate.
Research and Development progress along with latest news related to each of the Klebsiella pneumoniae pipeline candidates is included.

Major companies participating in therapeutic development of Klebsiella pneumoniae are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Klebsiella pneumoniae from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Klebsiella pneumoniae clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Klebsiella pneumoniae pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Klebsiella pneumoniae pipeline report includes
- Panorama of Klebsiella pneumoniae pipeline markets including statistics on therapeutic drugs and companies involved

- Klebsiella pneumoniae Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

- Klebsiella pneumoniae pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study

- Overview of companies participating in Klebsiella pneumoniae pipeline with short introduction to their businesses and pipeline projects

- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

- Research and Development progress and trial details, results wherever available, are also included in the pipeline study

- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Klebsiella pneumoniae pipeline therapeutics

Reasons to Buy
- Get clear understanding of the entire Klebsiella pneumoniae pipeline, with details on active projects

- Get in detail information of each product with updated information on each project along with key milestones

- Know the list of companies participating in global Klebsiella pneumoniae pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data

- Get trial information for each pipeline product under development

- Understand the pipeline structure in terms of mechanism of Action, phase and company

Our reports have been used by over 10K customers, including:

Get Industry Insights. Simply.

Latest reports & slideshows with insights from top research analysts
150+ Million searchable statistics with tables, figures & datasets
More than 25,000 trusted sources

Single User License — provides access to the report by one individual.
Department License — allows you to share the report with up to 5 users
Site License — allows the report to be shared amongst all employees in a defined country
Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ

How we can help
- I am not sure if the report I am interested in will fulfill my needs. Can you help me?
- Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
- We buy reports often - can ReportLinker get me any benefits?
- Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
- I have had negative experiences with market research reports before. How can you avoid this from happening again?
- We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.
Report Delivery
- How and when I will receive my Report?
- Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
Payment conditions
- What payment methods do you accept?
- 1. Credit card : VISA, American Express, Mastercard, or
  2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
  3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
- What are ReportLinker’s Payment Terms?
- All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
- Are Taxes and duties included?
- All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
- I’m not satisfied. Can I be refunded?
- No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
User license
- The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

Purchase Reports From Reputable Market Research Publishers

Loncastuximab tesirine- Emerging Insight and Market Forecast-2030

$ 3250
February 2021
50 pages

“LONCASTUXIMAB TESIRINE- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse large B cell lymphoma in 7 Major Markets. ...